Andrew Lam Email

Sr. VP Technical Operations . Tranquis Therapeutics

Current Roles

Employees:
11
Revenue:
$1.7M
About
Tranquis Therapeutics is discovering and developing innovative medicines with the potential to revolutionize the management of neurodegenerative and aging-related diseases and to dramatically reduce the burden these illnesses place on patients, families and societies worldwide. Founded on ground-breaking neuro-immunology research from the laboratory of Professor Edgar Engleman, MD, at Stanford University, Tranquis' novel therapeutic approach targets underlying myeloid immune cell dysfunction that has been linked to a variety of nervous system disorders. The company's portfolio is comprised of small molecules which cross the blood-brain barrier, and the lead therapeutic candidate has demonstrated highly encouraging effects in challenging preclinical models of Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), Parkinson's Disease (PD), and age-related cognitive impairment. Tranquis plans to initiate development in orphan neurodegenerative diseases such as ALS and FTD and later expand into more prevalent diseases such as PD and Alzheimer's Disease. For more information, visit www.tranquis.com.
Tranquis Therapeutics Address
3 Lagoon Dr.
San Mateo, CA
United States
Tranquis Therapeutics Email

Past Companies

Tranquis Therapeutics, Inc.Sr. VP Technical Operations
Retrotope, Inc.VP CMC
Espero BioPharmaVP Product Development

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.